全文获取类型
收费全文 | 4469篇 |
免费 | 269篇 |
国内免费 | 9篇 |
专业分类
耳鼻咽喉 | 23篇 |
儿科学 | 421篇 |
妇产科学 | 161篇 |
基础医学 | 534篇 |
口腔科学 | 128篇 |
临床医学 | 255篇 |
内科学 | 1081篇 |
皮肤病学 | 109篇 |
神经病学 | 207篇 |
特种医学 | 133篇 |
外科学 | 591篇 |
综合类 | 142篇 |
一般理论 | 1篇 |
预防医学 | 215篇 |
眼科学 | 115篇 |
药学 | 238篇 |
中国医学 | 6篇 |
肿瘤学 | 387篇 |
出版年
2023年 | 35篇 |
2022年 | 92篇 |
2021年 | 149篇 |
2020年 | 81篇 |
2019年 | 117篇 |
2018年 | 152篇 |
2017年 | 104篇 |
2016年 | 155篇 |
2015年 | 149篇 |
2014年 | 189篇 |
2013年 | 235篇 |
2012年 | 368篇 |
2011年 | 360篇 |
2010年 | 209篇 |
2009年 | 139篇 |
2008年 | 255篇 |
2007年 | 283篇 |
2006年 | 212篇 |
2005年 | 201篇 |
2004年 | 179篇 |
2003年 | 155篇 |
2002年 | 168篇 |
2001年 | 92篇 |
2000年 | 108篇 |
1999年 | 78篇 |
1998年 | 41篇 |
1997年 | 29篇 |
1996年 | 22篇 |
1995年 | 22篇 |
1994年 | 20篇 |
1993年 | 14篇 |
1992年 | 36篇 |
1991年 | 47篇 |
1990年 | 24篇 |
1989年 | 39篇 |
1988年 | 22篇 |
1987年 | 24篇 |
1986年 | 16篇 |
1985年 | 15篇 |
1984年 | 12篇 |
1983年 | 14篇 |
1981年 | 6篇 |
1980年 | 6篇 |
1979年 | 5篇 |
1977年 | 5篇 |
1976年 | 11篇 |
1975年 | 4篇 |
1974年 | 5篇 |
1972年 | 7篇 |
1971年 | 5篇 |
排序方式: 共有4747条查询结果,搜索用时 265 毫秒
31.
We report a rare case of disseminated histoplasmosis in a immunocompetent young adult person involving bone marrow, liver, spleen and oral cavity. He presented with oral ulcers, weight loss and pancytopenia. His bone marrow aspiration examination revealed Histoplasma capsulatum. 相似文献
32.
33.
34.
V Kochupillai S Sharma S Francis A Nanu S Mathew P Bhatia H Dua L Kumar S Aggarwal S Singh 《Thymus》1987,10(1-2):95-102
Forty patients with severe aplastic anaemia received an intravenous infusion of 0.004 to 11.1 x 10(8) (median: 8 x 10(8) hematopoietic cells prepared from the fetal livers of 8-32 week old abortuses. Five patients, who died within 15 days of fetal liver infusion, are excluded from analysis. Twenty-two of the 35 evaluable patients (62%) responded favourably. Six of the 7 patients with good response were alive after 9 to 44 months (median: m = 20); one died 106 months after fetal liver infusion due to renal lithiasis. Four of the 7 with moderate response were alive after 9 to 31 months; 3 died within 16 months. Of 8 patients with minimal response, one was lost to follow-up and the others died in 3.4 to 10 months (m = 6). Median survival of responders was 15.7 months. Bone marrow cellularity became normal in 12 patients following fetal liver infusion. In seven patients, there was a relapse; 6 regained a normal bone marrow cellularity after a second or third fetal liver infusion. These data strongly suggest a role of fetal liver infusion in inducing bone marrow recovery. Of 13 non-responders, 4 were lost to follow-up and 9 died within 20 days-4.3 months (m = 1.6). Fetal liver infusion appears to be an effective therapy in patients with severe aplastic anaemia. 相似文献
35.
36.
Parul Jain Urmila Singh Vijay Kumar Rashmi Ratnam Amita Jain 《Indian journal of medical microbiology》2022,40(3):365-369
PurposeCartridge based nucleic acid amplification test (CBNAAT) has been endorsed by the WHO as the screening test for diagnosing extrapulmonary tuberculosis (EPTB). In the present study we report the agreement between CBNAAT (Xpert MTB/RIF), liquid culture (LC) and line probe assay (LPA) for diagnosis of Mycobacterium tuberculosis and detection of drug resistance among EPTB cases.MethodsThe EP samples were subjected to CBNAAT (Xpert MTB/RIF, Cepheid, USA) and wherever possible, to LC (MGIT 960, Becton Dickinson, USA) followed sequentially by first line and second line-LPA (FL-LPA, SL-LPA, Hain Lifescience, Germany) on the isolates.ResultsTotal 566/4080 (13.9%) EP samples were detected positive for M. tuberculosis on CBNAAT. Aspirates from lymph nodes were most often positive (11/30; 36.6%), followed by pus (240/873; 27.5%) and CSF samples (166/104; 15.8%). The detection of M. tuberculosis was more in adults than children except in tissue biopsy samples. Rifampicin resistance was also higher among adults except CSF in which resistance was more in children. Total 185 of 566 (32.7%) CBNAAT positive and 770 of 3510 (21.9%) CBNAAT negative samples could be cultured of which 110/185 (59.4%) and 33/770 (4.3%) respectively turned positive. FL-LPA and SL-LPA of 143 culture isolates showed that 27 isolates had drug resistance, of which 3 (2.1%) were XDR, 11 (7.7%) were Pre-XDR (FQ) and 13 (9.1%) were MDR. Of these 27 resistant isolates, 12 were negative by CBNAAT and two were mislabeled as Rifampicin sensitive or indeterminate based on the unique RpoB gene mutation patterns on LPA. The positive and negative agreements between LC and CBNAAT for detection of M. tuberculosis were 67.1% and 92.7% respectively and between LPA and CBNAAT for rifampicin resistance detection were 98.9% and 92.9% respectively.ConclusionsFor EPTB, CBNAAT should be accompanied with LC wherever possible irrespective of the CBNAAT result. 相似文献
37.
38.
Neurosurgical Review - Spinal dysraphism is an umbrella term describing herniation of meninges or neural elements through defective neural arch. They can be broadly categorized into open and closed... 相似文献
39.
Daniel B. Buchalter David J. Kirby Greg M. Teo Richard Iorio Vinay K. Aggarwal William J. Long 《The Journal of arthroplasty》2021,36(1):286-290.e1
BackgroundVancomycin powder and dilute povidone-iodine lavage (VIP) was introduced to reduce the incidence of periprosthetic joint infection (PJI) in high-risk total knee arthroplasty (TKA) patients. We hypothesize that VIP can reduce the incidence of early PJI in all primary TKA patients, regardless of preoperative risk.MethodsAn infection database of primary TKAs performed before a VIP protocol was implemented (January 2012-December 2013), during a time when only high-risk TKAs received VIP (January 2014-December 2015), and when all TKAs received VIP (January 2016-September 2019) at an urban, university-affiliated, not-for-profit orthopedic hospital was retrospectively reviewed to identify patients with PJI. Criteria used for diagnosis of PJI were the National Healthcare Safety Network and Musculoskeletal Infection Society guidelines.ResultsVIP reduced early primary TKA PJI incidence in both the high-risk and all-risk cohorts compared with the pre-VIP cohort by 44.6% and 56.4%, respectively (1.01% vs 0.56% vs 0.44%, P = .0088). In addition, after introducing VIP to all-risk TKA patients, compared with high-risk TKA patients, the relative risk of PJI dropped an additional 21.4%, but this finding did not reach statistical significance (0.56% vs 0.44%, P = .4212). There were no demographic differences between the 3 VIP PJI cohorts.ConclusionVIP is associated with a reduced early PJI incidence after primary TKA, regardless of preoperative risk. With the literature supporting its safety and cost-effectiveness, VIP is a value-based intervention, but given the nature of this historical cohort study, a multicenter randomized controlled trial is underway to definitively confirm its efficacy. 相似文献
40.
Yuki Bekki Josep Marti Takeo Toshima Sara Lewis Amita Kamath Pamela Argiriadi William Simpson Lucas Facciuto Rahul S. Patel Ganesh Gunasekaran Edward Kim Thomas D. Schiano Marcelo E. Facciuto 《Surgery》2021,169(5):1044-1051
BackgroundPortal vein embolization before liver resection is considered the therapy of choice for patients with inadequate future liver remnants. The concept of radioembolization with Yttrium-90 to achieve the same goal has limited data.MethodsWe retrospectively compared patients who underwent portal vein embolization and Yttrium-90 lobectomy before resection of hepatocellular carcinoma in patients with chronic liver disease.ResultsSeventy-three patients underwent portal vein embolization and 22 patients underwent Yttrium-90. Forty-seven percent of patients before portal vein embolization required additional procedures for tumor control, and 27% of patients after Yttrium-90 required additional procedure to mainly induce further hypertrophy. Both therapies achieved the goal of future liver remnants >40%, but the degree of hypertrophy was significantly higher in Yttrium-90 patients (63% for Yttrium-90, 36% for portal vein embolization, P < .01). Tumor response was significantly better with Yttrium-90, achieving complete response in 50% of patients. Resectability rate was higher after portal vein embolization (85% for portal vein embolization, 64% for Yttrium-90, P = .03). Tumor progression was the most common reason precluding surgery. Complete tumor control was the reason not to pursue surgery in 18% of patients after Yttrium-90.ConclusionBoth preoperative portal vein embolization and Yttrium-90, increases liver resectability rates by inducing hypertrophy of future liver remnants in patients with hepatocellular carcinoma and chronic liver disease. Yttrium-90 lobectomy achieved better tumor control and provided more time to assess therapy response, optimizing the indication for surgery. 相似文献